TSCAN THERAPEUTICS INC. - COMMON STOCK
2.2300
21-February-25 10:56:40
15 minutes delayed
Stocks
+0.0400
+1.83%
Today's range
2.1500 - 2.2987
ISIN
N/A
Source
NASDAQ
-
TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
02 Jun 2022 07:00:01 By Nasdaq GlobeNewswire
-
31 May 2022 07:00:00 By Nasdaq GlobeNewswire
-
19 May 2022 07:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
17 May 2022 07:00:02 By Nasdaq GlobeNewswire
-
12 May 2022 07:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
09 May 2022 07:00:02 By Nasdaq GlobeNewswire
-
02 May 2022 17:02:38 By Nasdaq GlobeNewswire
-
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, Finance
11 Apr 2022 07:00:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities
09 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in Upcoming Investor Conferences
02 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
10 Feb 2022 07:00:02 By Nasdaq GlobeNewswire
-
24 Jan 2022 07:00:01 By Nasdaq GlobeNewswire
-
TScan Outlines 2022 Priorities as Programs Enter Clinic
10 Jan 2022 07:00:03 By Nasdaq GlobeNewswire
-
13 Dec 2021 09:16:14 By Nasdaq GlobeNewswire
-
03 Dec 2021 07:00:00 By Nasdaq GlobeNewswire
-
TScan Therapeutics Establishes Facility to Manufacture T Cell Receptor Engineered T Cell Therapies
02 Dec 2021 07:00:01 By Nasdaq GlobeNewswire
-
TScan Therapeutics to Participate in Upcoming Investor Conferences
11 Nov 2021 07:00:01 By Nasdaq GlobeNewswire
-
10 Nov 2021 07:00:02 By Nasdaq GlobeNewswire
-
04 Nov 2021 09:30:32 By Nasdaq GlobeNewswire